Maxim Group analyst Jason McCarthy maintained a Buy rating on Gain Therapeutics yesterday and set a price target of $7.00.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Jason McCarthy has given his Buy rating due to a combination of factors related to Gain Therapeutics’ lead Parkinson’s disease program, GT-02287. He highlights the upcoming January 6 key opinion leader (KOL) event as an important catalyst, where detailed Phase 1b data in Parkinson’s patients will be discussed, potentially validating the company’s therapeutic approach. The current share price of $3.16 is viewed as attractive relative to the $7.00 price target, implying meaningful upside if the clinical and strategic milestones are met.
McCarthy’s stance also reflects confidence in the broader development strategy behind GT-02287 and the company’s progress toward de-risking this asset through patient data. The scheduled expert discussion suggests growing scientific and clinical interest, which, if positive, could enhance investor visibility and support a higher valuation. Taken together, the near-term clinical readouts, structured investor outreach, and favorable risk-reward profile underpin his Buy recommendation on GANX.
In another report released on December 19, H.C. Wainwright also reiterated a Buy rating on the stock with a $8.00 price target.
GANX’s price has also changed dramatically for the past six months – from $1.800 to $3.050, which is a 69.44% increase.